Exclusive: OpenAI has acquired Orchestra Bio
Rival AI giants OpenAI, Anthropic continue to push into science.
TL;DR
- OpenAI has acquired Orchestra Bio, a startup developing AI agents for pharmaceutical drug development.
- Orchestra's platform allows AI agents to handle tasks such as monitoring studies and identifying potential delays.
- The acquired technology will be integrated into OpenAI's Rosalind suite for life sciences researchers.
- Rival AI companies like Anthropic are also aggressively expanding into the life sciences sector.
- Anthropic previously acquired Coefficient Bio and launched Claude Science and a biological research lab.
- The acquisition aims to accelerate drug development timelines, which typically take 10-15 years.
- The AI race is increasingly focused on applying AI intelligence across various industries.